BRIEF

on BIOMERIEUX (EPA:BIM)

Exor Increases Stake in bioMérieux

Stock price chart of BIOMERIEUX (EPA:BIM) showing fluctuations.

Exor N.V. announced an increase in its stake in bioMérieux from 3.87% to 8.53%, alongside Institut Mérieux, which remains the majority shareholder. This move highlights Exor's confidence in bioMérieux, a leader in in vitro diagnostics. The transaction involves exchanging part of Exor's Institut Mérieux shares for bioMérieux shares and is expected to complete by December 2026, pending approvals.

Following the transaction, Institut Mérieux will hold 55.24% of bioMérieux's capital. Exor's shareholding in Institut Mérieux will be adjusted to 5.02%. Benoît Ribadeau-Dumas is proposed as Exor's representative on bioMérieux's board, reinforcing their involvement. There is no intent for a concerted action between Exor and the Mérieux family regarding bioMérieux.

Alexandre Mérieux and John Elkann expressed mutual trust and commitment, emphasizing the long-term growth and public health aims of both families. Pierre Boulud, CEO of bioMérieux, sees this as a strong endorsement of their strategy and growth potential.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BIOMERIEUX news